Treatments for autoimmune, inflammatory and allergic diseases are widely available. Yet the response to therapy and also disease progression is unpredictable and varies from patient to patient.
Identifying biomarkers and molecular mechanisms
With the 3TR project - taxonomy, treatment, target and remission - researchers therefore seek to identify biomarkers and molecular mechanisms that underlie the response (or non-response) to treatment.
Launched in November 2019, the 3TR project investigates seven immune-mediated, allergic and inflammatory diseases, including asthma and COPD.
A step further towards personalised therapy for asthma and COPD patients
The project will contribute to an improved personalised therapy, among others for asthma and COPD patients. It is funded by the Innovative Medicine Initiative (MI), a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
Bringing in the asthma and COPD patient’s perspective
EFA’s role in the 3TR project is to provide the allergy and respiratory patients’ perspective. To do so, EFA has set up a Respiratory Patients Working Group (RPWG), in collaboration with the European Lung Foundation (ELF). The group is composed of 16 asthma and COPD patients, providing their advice and revising clinical protocols.
Regular exchange between patients and researchers
To ensure that patients are at the core of the project’s activities, currently, we have monthly calls with patients and involved researchers.
Since the project started in November, patients have further been involved in the review of clinical protocols and play a fundamental role in identifying relevant indicators to assess patients’ wellbeing.
More information on the 3TR project can be found here.